(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(-0.82%) $83.16
(-1.16%) $1.619
(-0.42%) $2 337.40
(0.98%) $27.52
(0.66%) $928.20
(-0.16%) $0.933
(-0.12%) $11.01
(-0.23%) $0.799
(0.00%) $92.17
Live Chart Being Loaded With Signals
Daiichi Sankyo Company, Limited researches and develops, manufactures, imports, markets, and sells pharmaceutical products worldwide. The company offers trastuzumab deruxtecan, an anti-cancer agent and anti-HER2 antibody drug conjugate; mirogabalin for pain treatment; teneligliptin/canagliflozin for type 2 diabetes mellitus treatment; lacosamide anti-epileptic agent; prasugrel, an antiplatelet agent; denosumab for osteoporosis and bone disorders; teneligliptin for type 2 diabetes mellitus treatment; edoxaban, an anticoagulant; esomeprazole for ulcer treatment; memantine for treating Alzheimer's disease; and laninamivir for anti-influenza treatment...
Stats | |
---|---|
本日の出来高 | 3 668.00 |
平均出来高 | 21 247.00 |
時価総額 | 61.07B |
EPS | $20.86 ( 2023-10-31 ) |
Last Dividend | $0.113 ( 2023-03-30 ) |
Next Dividend | $0 ( N/A ) |
P/E | 46.84 |
ATR14 | $0.819 (2.57%) |
Daiichi Sankyo Company, 相関
10 最も正の相関 |
---|
10 最も負の相関 |
---|
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Daiichi Sankyo Company, 財務諸表
Annual | 2024 |
収益: | $1 601.69B |
総利益: | $1 186.37B (74.07 %) |
EPS: | $104.69 |
FY | 2024 |
収益: | $1 601.69B |
総利益: | $1 186.37B (74.07 %) |
EPS: | $104.69 |
FY | 2023 |
収益: | $1 278.48B |
総利益: | $914.95B (71.57 %) |
EPS: | $56.96 |
FY | 2022 |
収益: | $1 044.89B |
総利益: | $682.09B (65.28 %) |
EPS: | $34.94 |
Financial Reports:
No articles found.
Daiichi Sankyo Company, Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0.0940 (N/A) |
$0 (N/A) |
$0.113 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | $0.0980 | 2014-03-27 |
Last Dividend | $0.113 | 2023-03-30 |
Next Dividend | $0 | N/A |
Payout Date | 2011-12-01 | |
Next Payout Date | N/A | |
# dividends | 18 | -- |
Total Paid Out | $1.801 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 3.36 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 5.38 | |
Div. Directional Score | 8.94 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
SOUHY | Ex Dividend Junior | 2023-09-14 | Annually | 0 | 0.00% | |
HFBA | Ex Dividend Junior | 2023-09-14 | Semi-Annually | 0 | 0.00% | |
ANSLY | Ex Dividend Knight | 2023-08-23 | Semi-Annually | 0 | 0.00% | |
NSARO | Ex Dividend Knight | 2023-07-07 | Quarterly | 0 | 0.00% | |
CYFL | Ex Dividend Knight | 2023-09-05 | Quarterly | 0 | 0.00% | |
THYCF | Ex Dividend Junior | 2023-09-28 | Annually | 0 | 0.00% | |
IGGHY | Ex Dividend Knight | 2023-09-21 | Semi-Annually | 0 | 0.00% | |
BDULF | Ex Dividend Knight | 2023-09-12 | Annually | 0 | 0.00% | |
PPWLM | Ex Dividend Junior | 2023-07-19 | Quarterly | 0 | 0.00% | |
EKTAY | Ex Dividend Knight | 2023-08-25 | Semi-Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.125 | 1.500 | 7.49 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.0580 | 1.200 | 8.07 | 9.68 | [0 - 0.3] |
returnOnEquityTTM | 0.125 | 1.500 | 9.72 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0.335 | -1.000 | 6.65 | -6.65 | [0 - 1] |
currentRatioTTM | 3.01 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 1.522 | 0.800 | 5.75 | 4.60 | [0.8 - 2.5] |
cashRatioTTM | 0.895 | 1.500 | 6.14 | 9.21 | [0.2 - 2] |
debtRatioTTM | 0.0294 | -1.500 | 9.51 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 10.14 | 1.000 | 7.36 | 7.36 | [3 - 30] |
operatingCashFlowPerShareTTM | 312.54 | 2.00 | 10.00 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 248.50 | 2.00 | 10.00 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.0603 | -1.500 | 9.76 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.741 | 1.000 | 0.988 | 0.988 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.115 | 1.000 | 9.70 | 9.70 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 5.89 | 1.000 | 10.00 | 10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.463 | 0.800 | -0.248 | -0.199 | [0.5 - 2] |
Total Score | 12.50 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 48.16 | 1.000 | 5.24 | 0 | [1 - 100] |
returnOnEquityTTM | 0.125 | 2.50 | 9.82 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 248.50 | 2.00 | 10.00 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 0.00619 | 1.500 | 9.85 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 312.54 | 2.00 | 10.00 | 10.00 | [0 - 30] |
payoutRatioTTM | 0.335 | 1.500 | 6.65 | -6.65 | [0 - 1] |
pegRatioTTM | 0.0441 | 1.500 | -3.04 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.374 | 1.000 | 3.15 | 0 | [0.1 - 0.5] |
Total Score | 5.38 |
Daiichi Sankyo Company,
Daiichi Sankyo Company, Limited researches and develops, manufactures, imports, markets, and sells pharmaceutical products worldwide. The company offers trastuzumab deruxtecan, an anti-cancer agent and anti-HER2 antibody drug conjugate; mirogabalin for pain treatment; teneligliptin/canagliflozin for type 2 diabetes mellitus treatment; lacosamide anti-epileptic agent; prasugrel, an antiplatelet agent; denosumab for osteoporosis and bone disorders; teneligliptin for type 2 diabetes mellitus treatment; edoxaban, an anticoagulant; esomeprazole for ulcer treatment; memantine for treating Alzheimer's disease; and laninamivir for anti-influenza treatment. It also provides olmesartan, an antihypertensive agent; levofloxacin, an antibacterial agent; pravastatin for hypercholesterolemia treatment; and loxoprofen, an anti-inflammatory analgesic. In addition, the company offers colesevelam for treating hypercholesterolemia and type 2 diabetes mellitus treatment; and ferric carboxymaltose and iron sucrose injections for treating anemia. Further, it provides Lulu, a combination cold remedy; Loxonin S, an antipyretic analgesic /anti-inflammatory analgesic; Transino for melasma improvement and treating against spots and freckles; Minon, a skincare product; and Breath Labo and Clean Dental oral care products, as well as Silodosin for dysuria; Gefitinib for malignant tumours; Bicalutamide for prostate cancer; and Tamoxifen, an anti-breast cancer agent. Additionally, the company offers adsorbed cell culture-derived influenza, influenza HA, measles rubella combined, and mumps vaccines. It also provides pharmaceuticals and drugs for animals, cosmetics, medical equipment, food products, drinking water, active pharmaceutical ingredients, and intermediates. It has collaboration with Guardant Health to develop Guardant360 CDx as a companion diagnostic for Enhertu in advanced metastatic non-small cell lung cancer. The company was founded in 1899 and is headquartered in Tokyo, Japan.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。